Why the study?
Does DuP 753 improve baroreceptor reflex function compared to captopril in high-renin hypertensive rats?
Does DuP 753 improve baroreceptor reflex function compared to captopril in high-renin hypertensive rats?
In high-renin hypertensive rats, the AT1 receptor blocker DuP 753 improved baroreceptor reflex bradycardia, whereas captopril did not, despite captopril producing a greater reduction in arterial pressure.
May restore baroreflex function in high-renin rat models; hypothesis-generating for differential AT1 versus ACE inhibitor effects in humans.
High-renin hypertensive rats exhibit a general impairment of the baroreceptor reflexes. In the present study we compared the effect of the angiotensin converting enzyme inhibitor captopril (10 mg/kg per day) with the effect of the selective angiotensin subtype 1 receptor blocker DuP 753 (10 mg/kg per day) on the baroreceptor reflex bradycardia (progressive doses of phenylephrine) and baroreceptor reflex tachycardia (progressive doses of nitroprusside) in conscious rats 7 days after aortic ligation. Arterial pressure was markedly reduced after both acute (15-minute) treatment with captopril (123 +/- 6 versus 184 +/- 23 mm Hg) and DuP 753 (140 +/- 10.5 versus 181 +/- 5.4 mm Hg), but the depressed baroreceptor reflex bradycardia increased only after DuP 753 (1.13 +/- 0.22 versus 0.75 +/- 0.60 beats per minute [bpm]/mm Hg) and remained attenuated after captopril (0.54 +/- 0.086 versus 0.30 +/- 0.07 bpm/mm Hg). After a 2-day treatment, captopril reduced arterial pressure (95 +/- 5 versus 184 +/- 2.3 mm Hg) to lower levels than DuP 753 (119 +/- 6 versus 172 +/- 4.6 mm Hg), whereas the depressed baroreceptor reflex bradycardia remained unchanged with captopril (0.46 +/- 0.13 versus 0.31 +/- 0.076 bpm/mm Hg) and increased with DuP 753 (1.13 +/- 0.19 versus 0.38 +/- 0.12 bpm/mm Hg). Neither DuP 753 nor captopril administered acutely (15 minutes) or for 2 days significantly altered the depressed baroreceptor reflex tachycardia.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Moreira et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: